Article Information
PubMed
Print ISSN
Online ISSN
History
- Received May 5, 2004
- Accepted September 14, 2004
- Published online November 23, 2004.
Article Versions
- Earlier version (September 15, 2004 - 12:11).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Susan J. Smith,
- Lenora B. Cieslinski,
- Robert Newton,
- Louise E. Donnelly,
- Peter S. Fenwick,
- Andrew G. Nicholson,
- Peter J. Barnes,
- Mary S. Barnette and
- Mark A. Giembycz
- Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom (S.J.S., L.E.D., P.S.F., P.J.B.); Respiratory, Inflammation and Respiratory Pathogens Center for Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania (L.B.C., M.S.B.); Department of Histopathology, Royal Brompton Hospital, London, United Kingdom (A.G.N.); and Departments of Cell Biology and Anatomy (R.N.) and Pharmacology and Therapeutics (M.A.G.), Respiratory Research Group, University of Calgary, Calgary, Alberta, Canada
- Address correspondence to:
Dr. Mark A. Giembycz, Department of Pharmacology and Therapeutics, Respiratory Research Group, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, Canada T2N 4N1. E-mail: giembycz{at}ucalgary.ca
Statistics from Altmetric.com
Article usage
In this issue
Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement